BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol. 2008;158:607-610. [PMID: 18076707 DOI: 10.1111/j.1365-2133.2007.08369.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
2 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
3 Vivero-Escoto JL, Taylor-Pashow KM, Huxford RC, Della Rocca J, Okoruwa C, An H, Lin W, Lin W. Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance. Small. 2011;7:3519-3528. [PMID: 22069305 DOI: 10.1002/smll.201100521] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
4 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
5 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
6 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
7 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
8 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ocazionez D, Dicks DL, Favinger JL, Shroff GS, Damani S, Kicska GA, Reddy GP. Magnetic Resonance Imaging Safety in Cardiothoracic Imaging. Journal of Thoracic Imaging 2014;29:262-9. [DOI: 10.1097/rti.0000000000000108] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Vivero-Escoto JL, Rieter WJ, Lau H, Huxford-Phillips RC, Lin W. Biodegradable polysilsesquioxane nanoparticles as efficient contrast agents for magnetic resonance imaging. Small 2013;9:3523-31. [PMID: 23613450 DOI: 10.1002/smll.201300198] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
11 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
12 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 158] [Article Influence: 17.2] [Reference Citation Analysis]
13 Darrah TH, Prutsman-pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1:479. [DOI: 10.1039/b905145g] [Cited by in Crossref: 183] [Cited by in F6Publishing: 138] [Article Influence: 15.3] [Reference Citation Analysis]
14 Leung N, Shaikh A, Cosio FG, Griffin MD, Textor SC, Gloor JM, Schwab TR, Larson TS, Dean PG, Prieto M, Nyberg SL, Stegall MD, Lee CU, Pittelkow MR. The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation 2010;10:558-62. [DOI: 10.1111/j.1600-6143.2009.02959.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Thakral C, Abraham JL. Gadolinium-Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis. Journal of Cutaneous Pathology 2009;36:1244-54. [DOI: 10.1111/j.1600-0560.2009.01283.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
16 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
17 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 73] [Article Influence: 8.5] [Reference Citation Analysis]
18 Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 2010;183:27-33. [PMID: 19913804 DOI: 10.1016/j.juro.2009.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
19 Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-70. [DOI: 10.1002/9781444317633.ch45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]